ArticleJMIR public health and surveillance2026
Comparison of In Vitro Metrics With Real-World Risk of Drug-Induced Parkinsonism Due to Antipsychotic Drugs: Retrospective Cohort Study.
Article in JMIR public health and surveillance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-induced parkinsonism (DIP) predominantly occurs due to antipsychotic drugs (APDs) blocking dopamine D2 receptors (D2Rs). However, in vitro assays often fail to fully reflect real-world variability in clinical outcomes. Objective: This study aimed to evaluate whether in vitro pharmacological metrics correspond to real-world risk of DIP associated with APD use. Methods: For 8 commonly used APDs, key in vitro parameters-including inhibition constants (Ki) of D2Rs and the serotonin 2A receptor, reversal rate (Kr) of D2Rs, and blood-brain barrier (BBB) penetration rate-were compiled to construct 6 composite DIP risk metrics. The real-world DIP risk was assessed using the Seoul National University Hospital common data model (2002-2021). APD users were matched 1:1 to selective serotonin reuptake inhibitor users using propensity score matching, and Cox proportional hazard regression was performed to estimate the hazard ratios (HRs) for DIP risk. Correlation between each in vitro metric and real-world DIP risk was evaluated using logarithmic regression models. Results: Among 44,664 patients from 8 matched cohorts, haloperidol showed the highest DIP risk (HR=4.56, 95% CI 2.29-9.07), whereas aripiprazole exhibited the lowest risk (HR=2.11, 95% CI 1.56-2.86). Metric 4 (pKr × BBB penetration rate) exhibited the strongest correlation with real-world DIP risk (R2=0.95). The correlation decreased when aripiprazole, a partial D2R agonist, was included in the analysis (R2=0.58). Conclusions: Integrating receptor-binding kinetics with BBB penetration may provide an in vitro framework that reflects real-world variation in DIP risk among D2R-antagonizing APDs. These findings support the relevance of combining kinetic and central nervous system exposure parameters for early safety evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.